GLI-2和SFRP-1在髓母细胞瘤中的表达及其意义  

Expressions and significances of GLI2 and SFRP-1 in medulloblastoma

作　　者：何密斯[1,2,3] 李昱[2,3,4] 林晓[4] 郑维萍[5] 唐俐[1,2,3] 

机构地区：[1]重庆医科大学病理生理教研室,重庆400016 [2]重庆医科大学神经科学中心,重庆400016 [3]重庆市神经生物学重点实验室,重庆400016 [4]重庆医科大学病理学教研室,重庆400016 [5]重庆医科大学实验教学管理中心,重庆400016

出　　处：《中国生物制品学杂志》2012年第11期1520-1523,共4页Chinese Journal of Biologicals

基　　金：重庆市科委自然科学基金资助项目(编号:CSTC;2009BB5064)

摘　　要：目的探讨GLI-2(GLI family zinc finger 2)和SFRP-1(Secreled frizzled-related protein 1)在髓母细胞瘤(Medulloblastoma,MB)组织中的表达及其意义。方法采用SP免疫组化法检测32份MB组织中GLI-2和SFRP-1的表达,分析两种蛋白之间及其与MB临床病理特征之间的相关性。结果 32例MB中,GLI-2和SFRP-1的阳性表达率分别为50%(16/32)和68.75%(22/32);MB中GLI-2和SFRP-1的表达在不同年龄、性别、肿瘤大小及部位中,差异均无统计学意义(P>0.05);SFRP-1在SHH-MB与NON-SHH-MB中的表达差异有统计学意义(P<0.001);GLI-2与SFRP-1在MB中的表达呈显著正相关(P<0.001)。结论 GLI-2和SFRP-1的异常表达可能对MB的发生、发展起一定的作用。GLI-2和SFRP-1可作为MB重要的生物学指标,有助于对MB患者危险度评估及患者术后放化疗方案的选择。Objective To investigate the expressions and clinical significances of GLI2 and SFRP-1 in medulloblastoma（MB）.Methods The expressions of GLI2 and SFRP-1 in 32 MB tissue specimens were determined by immunohistochemical assay with SP staining,based on which the relationship between expressions of the two proteins as well as between the protein expression and clinical features of MB were analyzed.Results The positive rates of GLI2 and SFRP-1 in MB were 50%（16 / 32） and 68.75%（22 / 32） respectively,which showed no significant difference in the patients of different genders,at various ages,and with tumors at various sizes in various sites（P 0.05）.However,the expression levels of SFRP-1 in SHH-MB and NON-SHH-MB were significantly different（P 0.001）.The expression of GLI-2 was positively related to that of SFRP-1（P 0.001）.Conclusion The abnormal expressions of GLI2 and SFRP-1 may play an important role in the onset and progress of medulloblastoma,indicating that GLI-2 and SFRP-1 may be used as important biological indicators for evaluation of risk in patients and screening of protocol for radiotherapy and chemotherapy after surgery.

关 键 词：髓母细胞瘤 GLI-2 SFRP-1 

分 类 号：R733.3[医药卫生—肿瘤] R73-35[医药卫生—临床医学]